hiPSC-Derived Perinatal MSCs Scalable Production
Solution Overview
Problem
The limited availability of perinatal mesenchymal stem cells from placental and umbilical cord tissues hinders their scalability for therapeutic use, particularly in treating conditions like cytokine storms related to viral infections, due to restricted cell numbers and manufacturing challenges.
Innovation Solution
Differentiating perinatal mesenchymal stem-like cells from human induced pluripotent stem cells (hiPSCs) using a defined trophoblast cell stage under serum-free conditions, enabling large-scale production of perinatal mesenchymal stem cells that can release anti-inflammatory and immunomodulatory paracrine factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If perinatal mesenchymal stem cells are harvested from placenta and umbilical cord during childbirth, then the cells can be obtained with authentic perinatal characteristics, but the total cell number is very limited and difficult to scale up for manufacturing
Solution Approach 1:
The patent creates perinatal-like mesenchymal stem cells by differentiating hiPSCs through a trophoblast intermediate stage, producing copies that replicate the functional characteristics of authentic perinatal MSCs without requiring actual perinatal tissues. This copying approach enables unlimited production while maintaining the desired cell properties
Solution Approach 2:
The patent performs preliminary reprogramming of somatic cells to hiPSCs and establishes defined differentiation protocols with specific growth factors and cytokines before large-scale production is needed. This preliminary preparation of differentiation pathways enables rapid scaling when clinical demand arises
2Stability of the object's composition
If perinatal mesenchymal stem cells are isolated from primary perinatal tissues, then the cells maintain their natural properties, but the availability is limited and manufacturing is difficult to scale up
Solution Approach 1:
The patent develops a universal differentiation protocol that can produce perinatal-like MSCs from hiPSCs in multiple locations and at various scales. The standardized protocol using defined growth factors (BMP-4, FGF-2, dexamethasone) and cytokines (IL-6, TNF-α, TGF-β) ensures consistent cell properties regardless of production site, enabling both research and clinical manufacturing
Solution Approach 2:
The patent controls cell differentiation by systematically changing parameters including growth factor concentrations, cytokine combinations, and incubation times. This parameter optimization ensures that differentiated cells consistently achieve the desired perinatal-like characteristics with low heterogeneity across large-scale productions
3Productivity
If large-scale production of perinatal mesenchymal stem cells is attempted from primary tissues, then more cells can be obtained, but the cell population heterogeneity and biological variations increase
Solution Approach 1:
By copying the developmental pathway from hiPSCs through trophoblast intermediates to perinatal-like MSCs, the patent ensures that all produced cells follow the same differentiation trajectory. This controlled copying process generates homogeneous cell populations with consistent properties, avoiding the heterogeneity that would arise from mixing cells from multiple primary tissue sources
Solution Approach 2:
The patent uses trophoblast cells as an intermediary stage in the differentiation process. This intermediate step acts as a controlled transition zone that directs hiPSCs toward a uniform perinatal-like MSC phenotype, reducing population heterogeneity while enabling large-scale production through standardized protocol steps
Data Source
AI summary
Non-naturally occurring perinatal mesenchymal stem cells differentiated from human induced pluripotent stem cells. The differentiation medium includes an amount of SB431542, an amount of BMP-4, and an amount of PD173074 and is repeated over the course of six days period until perinatal mesenchymal stem-like cells are formed. The resulting non-naturally occurring perinatal mesenchymal stem cells exhibit the relevant characteristics of naturally occurring perinatal mesenchymal stem cells, such as the positive expression of the mesenchymal stem cell markers CD73, CD90, and CD105. The non-naturally occurring perinatal mesenchymal stem cells may be used to produce paracrine factors and similar compounds for therapeutic purposes.